Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Clinical trial NCT02446236 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02446236
- Sponsor
- Hackensack Meridian Health
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-18
- Primary completion
- 2017-01-03
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.